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REM Sleep Behavior Disorder (RBD) is a chronic sleep condition characterized by
dream enactment and loss of REM atonia. Individuals often present to clinic with
complaints of injury to themselves or their bed-partner due to violent movements during
sleep. RBD patients have a high risk of developing one of the neurodegenerative α-
synucleinopathy diseases: over 70% will develop parkinsonism or dementia within 12
years of their diagnosis. RBD patients also exhibit accelerated disease progression and
a more severe phenotype than α-synucleinopathy sufferers without RBD. The disease’s
low prevalence and the relatively limited awareness of the condition amongst medical
professionals makes the diagnosis and treatment of RBD challenging. Uncertainty in
patient management is further exacerbated by a lack of clinical guidelines for RBD patient
care. There are no binary prognostic markers for RBD disease course and there are
no clinical guidelines for neurodegeneration scaling or tracking in these patients. Both
clinicians and patients are therefore forced to deal with uncertain outcomes. In this review,
we summarize RBD pathology and differential diagnoses, diagnostic, and treatment
guidelines as well as prognostic recommendations with a look to current research in
the scientific field. We aim to raise awareness and develop a framework for best practice
for RBD patient management.
Keywords: REMsleep behavior disorder (RBD), Parkinson’s disease, prodromal Parkinson’s disease, sleep
disorders, neurology, neuroscience, sleep
SYMPTOMS AND DIAGNOSTIC CONSIDERATIONS
Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) is a non-familial sleep disorder,
characterized by the loss of the inherent muscle atonia observed during normal REM sleep.
This phenomenon is often referred to as REM Sleep without Atonia (RSWA). Whilst isolated
RSWA is frequently an incidental finding in sleep studies, it forms the substrate of the dream
enactment behavior which defines RBD. Here, individuals experience vivid dreams which they act
out during sleep.
It is important to remember that dream enactment and limb movements during sleep can
occur in the healthy population, often in the context of heightened emotional states (1–3).
The same symptoms may also be experienced during withdrawal from sedatives or alcohol. In
non-pathological dream enactment, individuals typically respond to dream content during the
transition from REM sleep to the awake state and while maintaining REM atonia during much of
the REM period. In contrast, RBD individuals will maintain REM sleep during and immediately
after most of their dream enactments. As acute dream enactment is generally self-limiting, the
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chronicity of symptoms (>6 months) is a key distinguishing
factor, and forms part of the diagnostic criteria for RBD (4).
Anecdotally, dreams are often reported by patients with RBD
as violent or aggressive, resulting in violent motor behaviors
which may pose a threat to them or their bedpartner (5).
Whilst accounts of individuals kicking, punching, biting, or even
strangling their bedpartners during sleep paint an emotive image
of the condition and often capture public interest, they are
prone to recall bias. More systematic studies have revealed that
violent dreams and behaviors only make up a small percentage
of all events (6–8). When a dream enactment is occurring,
the individual’s eyes will remain closed as they engage with
the dream environment and their movements are generally
contained to their immediate surroundings, thus differentiating
these episodes from NREM parasomnias such as sleepwalking
(4). Upon awakening from a large motor event, the RBD
individual will be alert and orientated to their surroundings (4).
The frequency of motor events may vary greatly between
RBD individuals; ranging from multiple episodes per night, to
one episode per month (9). In any one patient, the severity and
frequency of the behaviors may also vary from night to night, and
over the course of their condition (10). The mechanisms behind
this fluctuation remains unknown.
Etiology
The behavioral states of wake and sleep are initiated and
maintained by complex interplay between multiple brainstem
and diencephalic nuclei. Dysregulation, disease or degeneration
of these nuclei can result in sleep disorders, such as narcolepsy,
and subtle changes to sleep-wake patterns. In the case of RBD,
the primary pathology appears to be an excitation/inhibition
imbalance in the brainstem nuclei controlling REMmuscle tone.
Movement during REM sleep is controlled by two systems:
one controls the input to spinal cord motoneurons to generate
muscle atonia (extrapyramidal), and the other controls motor
cortex activation to suppress locomotor activity (pyramidal).
The main generator of REM-sleep is the predominantly-
glutamatergic Subcoeruleus/Pre-Locus Coeruleus complex
[SubC/PC- analogous to the rat/mouse sublaterodorsal
nucleus (SLD)], which is anatomically situated just below
the noradrenergic locus coeruleus in the pons (11). As well as
projecting to many subcortical brain regions to promote and
maintain REM sleep, the SubC/PC projects caudally to control
the REM atonia neural network (12). Preceding and during
REM sleep, the REM-active SubC/PC excites the inhibitory
ventromedial medulla (VMM) and glycinergic neurons of
the spinal ventral horn, which in turn tonically hyperpolarize
spinal motor neurons (12, 13). This results in a temporary
paralysis of skeletal muscles and thus significantly reduced REM
muscle tone.
Disruption to this process results in abnormal motor
behaviors during REM sleep (Figure 1).
It is not definitively known whether RBD is caused by
an imbalance originating in the glutamatergic SubC/PC or
downstream in the GABA/Glycinergic VMM, though evidence
from animal studies suggest the latter is more likely (14). This
brainstem pathology does not exist in isolation. Given that
RBD is characterized not just by an increase in small sleep
twitches but also complex movements and dream enactment, it is
likely that abnormal disinhibition occurs in the pyramidal motor
tract during REM sleep, leading to execution of the complex
movements “imagined” by the motor cortex. Imaging studies
have shown that RBD can also be accompanied by changes in
multiple neurotransmitter systems, including the cholinergic,
noradrenergic, and dopaminergic circuits (15). Thus, one of the
key challenges in treating RBD derives from the uncertainty
surrounding its causative pathology and the extent of dysfunction
throughout the brain.
RBD may present on its own, often referred to as idiopathic
RBD (iRBD), or may exist as a secondary entity in the context
another condition. Regardless of cause, all RBD subtypes are
likely to reflect dysfunction at some point in the complex,
interconnected REM atonia circuits.
“Idiopathic” RBD
These patients usually present to sleep clinics with a history
of dream enacting behaviors and a present complaint of recent
sleep-related injury to themselves or their bedpartner, despite
no other health complaints or recent medication changes.
Whilst previously considered an idiopathic phenomenon, the
unquestionable link with alpha-synucleinopathies has challenged
this view.
Approximately 10 years after the first description of RBD in
the scientific literature, Schenck et al. reported the development
of parkinsonism in ∼40% iRBD individuals (16). Since then,
RBD has emerged as one of the most specific predictors of
the synuclein-mediated neurodegenerative diseases: Parkinson’s
disease (PD), Multiple System Atrophy (MSA) and Dementia
with Lewy Bodies (DLB). It is now estimated that up to 90%
of patients with “iRBD” will eventually develop one of the α-
synucleinopathies (17).
Given that RBD is found to occur, on average, 8 years
before the presentation of the core motor or cognitive symptoms
required for the clinically diagnosis of PD or DLB (18), there
is increasing evidence to suggest that in most cases RBD is
the early manifestation, or prodrome, of a clinically-defined
neurodegenerative disease. Indeed, detailed assessments often
reveal subtle features of these conditions, such as hyposmia,
constipation, or a slight tremor (19), that can often be missed
during a clinical consultation.
Whether any truly idiopathic RBD cases exist, or whether all
cases of iRBD will eventually convert to an α-synucleinopathy
given sufficiently follow-up time, is currently unknown.
However, given currently available evidence many in the field
have moved away from the idiopathic label (3).
Secondary RBD
The onset of RBD symptoms may coincide with the initiation of
certain drugs (20), the most common being the anti-depressant
SSRIs (21) which cause RBD behaviors in up to 6% of users (22).
Treatment using SSRIs results in increased serotonergic tone
during both wakefulness and sleep, which in turn may interfere
with mechanisms of REM atonia (21).
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FIGURE 1 | Key brain regions and neurotransmitters involved in regulation and maintenance of the REM sleep stage under healthy normative or pathological RBD
conditions. In RBD, dysfunction within the SubC→VMM→Spinal Motor Neuron pathway results in a lack of REM atonia (depicted with dotted line). BF, basal forebrain;
LC, locus coeruleus; LDT/PPT, laterodorsal tegmentum/pedunculopontine tegmentum; LH, lateral hypothalamus; Subc/PC, subcoeruleus/pre-locus coeruleus; TMN,
tuberomammillary nucleus; vlPAG, ventrolateral periaqueductal gray; VLPO/MnPO, ventrolateral preoptic nucleus/median preoptic nucleus; VMM, ventromedial
medulla. Figure created using BioRender.com.
Other examples of secondary RBD include those caused
by neurological lesion affecting sleep/wake regulatory brain
regions, most commonly within the brainstem. RBD due
to lesions is rare and most commonly associated with
meningiomas and subsequent disruption of pontine REM-
atonia structures (23), although cases of narcolepsy (24),
pontine cavernoma (25), pontine lymphoma (26), multiple
sclerosis (27), and acute inflammatory rhombencephalitis
(28) all give further examples of RBD incidence secondary
to lesion.
Though RBDmay precede the diagnosis of a clinically-defined
neurodegenerative disease, as seen in the majority of “idiopathic”
RBD patients, it often emerges concomitantly around the same
time or subsequent to a synucleinopathy diagnosis. The focus
on RBD as a prodrome often leaves concomitant RBD, or RBD
secondary to neurodegeneration, to fall by the wayside, with the
distinction and prevalence of such cases in the α-synucleinopathy
populations seldom reported in the literature.
RBD occurs concomitantly in up to 40% of PD patients (29),
with studies suggesting the majority of PD patients develop
RBD alongside or after their first parkinsonian symptoms (30,
31). These individuals also exhibit a more advanced disease
profile (30), with greater cognitive impairment (31) compared
to those whose RBD preceded their PD, warranting further
investigation into the temporal spread of neurodegeneration
in α-synucleinopathies. For DLB and MSA, prevalence of
concomitant RBD may be as high as 76% (32) and 88% (33),
respectively, though no research has investigated the timing of
RBD occurrence in these populations.
The temporal variation in RBD occurrence highlights the
importance of differentiating between RBD as a prodrome and
as a concomitant symptom of α-synucleinopathies, especially
when conducting research to phenotype and stratify RBD in
α-synucleinopathic populations.
EPIDEMIOLOGY
RBD typically presents from the 6th decade of life onwards, with
cases of medication- or lesion-induced disease more commonly
seen in those under 50 years (34).
The true prevalence of RBD in the general population is
very difficult to gauge. Due to its REM state-specific occurrence,
individuals are often unaware of their behaviors. Therefore,
clinic-based estimates typically only capture those prompted to
seek medical advice by their bedpartner or, less frequently, those
that have injured themselves during violent dream enactment.
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Several studies have attempted to assess the prevalence in the
general population using screening questionnaires, finding the
rate of probable RBD to be 0.4–5% (35–37). These investigations
are not without their limitations—several conditions have similar
symptomology to RBD, including the increasingly common
condition obstructive sleep apnoea (38), and the aforementioned
prevalence rates are likely to include individuals without RBD.
Polysomnography screening of the general population gives a
more accurate RBD prevalence of∼1–2% (39–41).
Divergence between clinical and general population
representations of RBD are further demonstrated by reported
RBD sex differences. RBD is commonly regarded as a strongly
male-predominant disease, largely based on clinical cohorts
reporting a male to female ratio of 9:1 (42). This does not
reflect population-based studies, where an equal sex split is
reported (39). While sex differentials in disease can be due to
true pathological mechanisms, or persist due to gender-biased
underreporting, it is unknown which accounts for the sex
difference seen in RBD. It has been speculated that men are
naturally more aggressive than women and therefore are more
likely to experience violent dreams and RBD behaviors. However,
studies have shown that RBD dream content does not differ
between sexes (43, 44) and violent dreams are not associated
with higher testosterone levels (45). If and why women are
susceptible to underreporting RBD, as in the case of snoring
and obstructive sleep apnoea (46, 47), therefore needs further
investigation. Interestingly, male sex is an identified risk factor
for all of the α-synucleinopathies (48–51), though the reason for
this remains unknown.
As well as male sex and antidepressant use, large cross-
sectional cohort studies have consistently identified low
socioeconomic status and jobs with toxic environmental
exposures (e.g., farming or mining) as environmental risk
factors for RBD development (35, 36, 52). Additional measures
associated with compromised health—including smoking,
drinking, low physical activity, cardiovascular risk factors
(such as diabetes), and psychological distress—have also been
implicated (35, 36, 52). The complex interplay between most
of these factors is not specific to RBD and rather reflects
the influence of social structures upon population health.
Interestingly, the link between occupational and environmental
exposures (most notably pesticides) and RBD is one that mirrors
the PD population. The link between pesticides and MSA or
DLB is less clear (50, 53, 54), suggesting alternative triggers for
the specific strain pathology of these conditions.
RBD is non-familial and therefore susceptibility to disease
development is likely to be a combination of multiple
environmental and genetic determinants. Studies of RBD
genetics tend to center upon single nucleotide polymorphisms
(SNPs) and genetic mutations known to be associated with the α-
synucleinopathies. Genetic changes in RBD populations include
underrepresentation of a PD-protective MAPT (Microtubule
Associated Protein Tau) SNP (55), glucocerebrosidase missense
variant overrepresentation (56), altered clock gene expression
(57), and SNCA (Synuclein Alpha) gene variants (58). In each
instance, however, the mutations are present in only a small
minority of the RBD population thus limiting the conclusions
that can be drawn regarding genetic determinants of RBD.
Patient Presentation and Diagnosis
Of those that seek medical advice, patients will usually present
to their GP in the instance of self- or bedpartner injury due to
their dream-enacting behaviors. In the authors’ experience, this is
often a significant barrier to accessing help, with many patients,
and GPs, not recognizing RBD as a medical problem. This is
reflected by the diagnostic delay seen in RBD, cited between 7
and 9 years on average (59, 60).
When RBD is suspected outside of the setting of a designated
sleep clinic, simple screening questionnaires, such as the single-
question RBD1Q (61), or the more detailed RBDSQ (62), may be
used to prompt further assessment or onward referral.
Whilst these questionnaires hold some value when screening
for the disorder, they do not inherently encompass the diagnostic
criteria, and the cut-off points used are somewhat contentious
(63). Thus, these scales are yet to be used as a standardized
clinical resource.
Individuals suspected of having RBD should be referred
to a specialist Sleep Medicine or Neurology service for a
diagnostic assessment (see Figure 2 for an outline of the
RBD diagnostic process). Although there is likely significant
variability between the individual clinicians (as there are no
ICSD3 or other guidelines for RBD diagnostic assessment),
this initial outpatient clinical assessment broadly consists of a
general examination and neurological examination to rule out
differential diagnoses, coupled with several tests, and rating scales
designed to assess more specific sleep and neurodegenerative
aspects of the condition. Whenever possible, clinicians should
make use of any information from bed-partners, as they often
provide a more accurate history of sleep-related behaviors. These
are also the most reliable means to assess the severity of the
RBD, which, in turn, can aid management options. Clinicians
should additionally take detailed note of history indicative
of secondary RBD, as well as screen for α-synucleinopathic
prodromal symptoms such as hyposmia, constipation, and
cognitive changes.
Where indicated from the history and clinical examination,
further investigations e.g., brain MRI, may be required to
diagnose secondary RBD and inform treatment. The utility of
DaTSCAN for diagnosing RBD secondary to α-synucleinopathy
is often limited at this stage and is not recommended (see
“Current Research: RBD and the α-Synucleinopathies” section
for further discussion).
The gold-standard protocol for RBD diagnosis is a clinical
assessment coupled with a subsequent overnight video
polysomnography (v-PSG) study. The collective measures
from these form the basis of the most commonly used diagnostic
criteria, the International Classification of Sleep Disorders (3rd
Edition) (ICSD-3) (see Table 1).
While the diagnosis of probable RBD can be solely made
based on a detailed history, meeting points 1, 2, and 4 on
the ICSD-3 RBD Diagnostic Criteria, a confirmatory v-PSG
study is required for a formal diagnosis to be made. The v-
PSG is an inpatient sleep study, and therefore may require
the patient to be further referred to a specialist sleep center.
The study itself consists of electroencephalography (EEG) to
assess brain activity, electromyography (EMG) for muscle
activity, respiratory, oximetry, and heart rate monitoring and
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FIGURE 2 | Flow chart summarizing the process of RBD diagnosis.
TABLE 1 | Diagnostic criteria for REM sleep behavior disorder (4).
Criteria Description
1 Repeated episodes of sleep-related vocalization and/or
complex motor behaviors
2 These behaviors are documented by polysomnography to
occur during REM sleep or, based on clinical history of dream
enactment, are presumed to occur during REM sleep
3 Polysomnographic recording demonstrates REM sleep
without atonia (RSWA)
4 The disturbance is not better explained by another sleep
disorder, mental disorder, medication or substance abuse
All 4 criteria must be met for a definite RBD diagnosis. If v-PSG is not available, or RSWA
is not captured during v-PSG then a provisional diagnosis of RBD can be given if all other
criteria are met.
video recording of the patient while they sleep. It is also
advisable for the patient to undergo a next-day Multiple Sleep
Latency Test (MSLT) to control for excessive daytime sleepiness
and narcolepsy.
The minimum aim of the v-PSG is to capture RSWA, which
the ICSD-3 states is indicated by “excessive augmentation of
chin EMG” or “excessive chin or limb phasic EMG twitching”
during REM sleep (4). Scoring guidelines from the American
Academy of Sleep Science (AASM) quantitatively define these as
“a chin EMG amplitude greater than the minimum amplitude
demonstrated in NREM sleep” and “transient muscle activity
0.1–5.0 s in duration at least 4 times as high amplitude
as background EMG,” respectively (64). Such twitches occur
relatively frequently in RBD individuals so the likelihood of
capturing RSWA during a diagnostic v-PSG is high. It is the
large dream enactments and complex motor behaviors which
are less common (for instance, which an individual may only
experience once a month) and therefore rarer to capture during
the sleep study. Therefore, the diagnostic criteria allow for RBD
to be diagnosed based on v-PSG-confirmed RSWA with a history
of dream enactment or sleep behaviors, acknowledging the
limitations of a one-night sleep study for full phenotype capture.
The v-PSG requires not only a sleep center to physically host
the study, but also technicians to score and interpret the data. The
resources available to a health service will therefore determine
access to v-PSG.
Though seemingly an attractive option given the limited
access to sleep studies in most centers, the practice of solely
relying on clinical assessment or screening questionnaires is
likely to result in a significant number of false-positive diagnoses
(65). This is particularly pertinent in suspected idiopathic cases,
where a diagnosis of RBD should prompt discussion regarding
future risk of developing a neurodegenerative disorder (see “RBD
Prognosis and Communicating the Risks” section).
RBD PROGNOSIS AND COMMUNICATING
THE RISKS
The prognosis for RBD depends largely upon the subtype.
Patients diagnosed with RBD secondary to medication have
the most promising prognosis of RBD resolution once the
causative medication is withdrawn. However, it has been shown
that RBD may persist following cessation of SSRIs (66, 67),
and it is therefore possible that in some cases the medication
simply “unmasked” an already underlying pathology, triggering
early clinical presentation (22). For RBD secondary to defined
lesion e.g., inflammatory plaques, the main symptoms of RBD
can be controlled relatively reliably using a combination of
pharmacological and behavioral treatments. As these patient’s
present with chronic but stable neural tissue damage, their RBD
symptoms are unlikely to change over time.
For patients with RBD presenting as part of a clinically-
defined neurodegenerative condition, such as PD, MSA, or DLB,
the management of their sleep disorder should form part of
their holistic care. Generally, the presence of RBD marks a less-
favorable disease phenotype. In PD, for example, the presence
of concomitant RBD is associated with a greater non-motor
burden and a more adverse prognosis (68–71). There have been
no studies of whether the symptomatic treatment of RBD impacts
long-term outcomes in these patients.
Finally, for patients diagnosed with apparently idiopathic
disease, the prognosis remains uncertain. There are currently
no biomarkers or investigations to determine the personal
risk of developing an α-synucleinopathy. A recent metanalysis
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of the existing international prospective cohort studies found
that after an average follow up of 4.6 years, 352 (28%) of
1,280 RBD patients were diagnosed with a clinically defined
neurodegenerative disorder. Of those, 52% developed PD,
43.5% developed DLB, and 4.5% developed MSA (18). Color
vision deficits, hyposmia, erectile dysfunction and constipation
accompany the loss of REM sleep atonia in the “prodromal”
disease stages, before a cluster of additional symptoms including
cognitive deficits, urinary dysfunction and motor symptoms
arise in the “preclinical” stage, defined as <5 years before
diagnosable phenoconversion (72). Importantly, severity of all
prodromal and preclinical symptoms increases over time (72),
reinforcing the onus on clinicians to undertake vigilant symptom
tracking of RBD patients to inform patient management and
scientific research.
It is the responsibility of the clinician making the
diagnosis to sensitively and clearly communicate the risks
of neurodegeneration associated with RBD to their patients.
Although there are no official UK guidelines for the care of
RBD patients, it is in the patient’s best interest to be fully
informed of their condition (73). Not only does this respect
and maintain the autonomy of the patient, it also facilitates
the conversation of current RBD research and their potential
involvement (74). It is highly beneficial for the RBD and α-
synucleinopathy research fields if all patients diagnosed with
RBD, regardless of subtype but especially those with iRBD, are
encouraged to participate in experimental research. Further
to any clinician-patient conversations, patient counseling, and
advice services should be made available and recommended to
the individual.
RBD MANAGEMENT
Given the general uncertainty of causative pathology and
prognosis for RBD, the two greatest challenges for clinicians
remain the successful management of the condition, and in
the case of idiopathic or suspected prodromal RBD, symptom-
tracking for neurodegeneration indicators. An overview of RBD
patient management is provided in Table 2.
TREATMENT
The treatment of RBD falls into two categories: pharmacological
and behavioral. Unfortunately, as no cure for the disorder exists,
management remains symptomatic, with highest priority placed
on controlling the extreme and potentially injurious motor
behaviors. Many patients will, therefore, elect not to pursue any
treatment, especially when the impact of the condition on their
quality of life is low.
BEHAVIORAL
As there are no reported associations between daytime events
(e.g., stress, alcohol intake) and subsequent night-time RBD
behaviors (9), behavioral recommendations focus on the creation
TABLE 2 | Summary of RBD patient management recommendations according to condition subtype.
RBD subtype Recommendation Patient follow-up
First-line Second-line Third-line
Idiopathic iRBD Behavioral Clonazepam 0.25–0.5mg or
melatonin modified-release





Regular 6 month-1 year
follow-up. Review of current
treatments, dosage titration
if appropriate and
monitoring of any motor,
physiological, or cognitive
changes
Secondary Medication Cessation and replacement
of causative medication or








Initial short-term follow up




Lesion Behavioral Clonazepam 0.5mg or
melatonin modified-release





Initial short-term follow up




α-synucleinopathy Behavioral Clonazepam 0.25–0.5mg or
melatonin modified-release





Initial short-term follow up




Titration of clonazepam dosage should be within the ranges of 0.25 mg−2.0 mg/night. Doses of modified-release melatonin are in the range of 2–6mg, with higher doses up to 12mg
occasionally used.
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of a safe sleep-environment. This can include removing or
padding bedside furniture, or lowering the mattress and placing
pillows on the floor beside the bed in case of falls (75).
In some cases, it may be recommended for the patient and
bedpartner to sleep in separate beds to minimize injury.
Behavioral recommendations are applicable to both idiopathic
and secondary RBD patients, and the extent of these measures
should be appropriate to the severity and nature of the patient’s
RBD symptoms.
Besides changing the immediate sleep environment,
physicians should as always encourage patients to observe
good sleep hygiene and a healthy lifestyle. The lack of unique risk
factors for RBD will however limit the specificity, and likely the
efficacy, of this advice.
PHARMACOLOGICAL
Clonazepam is the generally the first-line agent used for the
treatment of RBD symptoms. It is long-acting benzodiazepine
with a half-life of 30–40 h, and typically commenced at a starting
dose of 0.25–1mg, taken nightly at bedtime. Clonazepam acts
to non-specifically enhance inhibitory processes within the brain
by binding to GABAA receptors, and thus temporarily quells
overactive or disinhibited brain regions which control REM
atonia, ultimately reducing the number of motor behaviors
during subsequent sleep. It was first explored as a treatment
for RBD given its efficacy in treating periodic leg movement
disorder (76), another sleep condition characterized by excessive
motor behaviors.
There have been no randomized, double-blind, controlled
trials of clonazepam in an iRBD population, and only a
handful of studies have looked at the effects of the drug on
sleep and RBD symptoms. Clonazepam somewhat restores the
EEG spectral profile of iRBD individuals to that of controls
when compared to their drug-naïve counterparts, as well as
improving both NREM and REM sleep stage stability (77, 78).
However, long-term clonazepam use did not affect subjective
measures such as daytime sleepiness (77) nor affect the REM
sleep atonia index (77, 78). Neither study captured complex,
violent REMmovements in either the drug-naïve or clonazepam-
treated iRBD groups and thus no conclusion can be drawn
on the efficacy of clonazepam in reducing the severity of
complex movements. However, if judged on RSWA index alone,
clonazepam use does not sufficiently control muscle tone during
RBD sleep.
Naturalistic follow-up studies have found similar results to
the above cross-sectional studies. Li et al.’s v-PSG follow-up
study found long-term clonazepam use increased the amount
of stage 2 NREM sleep but failed to reduce the amount of
REM sleep atonia in iRBD individuals; in fact, the amount of
total and tonic RSWA significantly increased over time despite
clonazepam use (79), demonstrating the progressive nature of the
condition. In a follow-up survey, the majority of iRBD patients
receiving clonazepam continued to experience sleep behaviors
despite treatment, though frequency, severity and number of
dream enactment behaviors were all reduced (80).
Over time, a number of patients will stop taking clonazepam
due to side effects, while many of those who remain on
clonazepam tend to experience the emergence of residual RBD
symptoms (79).
The above follow-up study outcomes are relatively standard
for long-term benzodiazepine use which, while a clinical
common practice (81), should in and of itself be carefully
considered case-by-case. Long-term benzodiazepine use is
generally defined as ≥6 months (81) and holds the greatest risk
for adverse effects such as cognitive impairment (82), dementia
development (83), and risk of falling (84), in aged populations.
While long-term benzodiazepine use in the elderly is generally
maintained at a stable, albeit higher than average, dosage (81)
it is common for clonazepam doses progressively over time in
the RBD population (79, 85). Underlying this are three potential
causes—dosage titration, the development of a tolerance to
clonazepam or a progressive worsening of RBD symptoms over
time. Long-term assessment of RBD symptoms does indeed show
the latter (79, 86), and in light of conflicting evidence for long-
term clonazepam tolerance in chronic conditions (87–89) it
should generally be assumed that clonazepam dosage should be
monitored closely to ensure sufficient control of RBD symptoms.
Clonazepam must be used with caution in the elderly,
individuals with a history of depression and those with airways
obstruction (90), such as obstructive sleep apnoea which is
commonly concomitant with RBD (91). Additionally, the long
half-life of clonazepam (92) can lead to “hangover” side effects
of excessive daytime sleepiness the next morning (79). Efforts to
replace or complement clonazepam therapy in unresponsive or
non-tolerant patients has led to the exploratory prescription of
alternative drugs with some success, namely in the prescription
of zopiclone (93), sodium oxybate (93), or pramipexole (94) [for
further review, see (95)]. As these cases are limited in size and are
not extensive case-controlled studies, clonazepam remains the
chosen pharmacological treatment for RBD, if only for the sole
reason of upholding the status quo.
Over recent years melatonin and associated melatonergic
agents have established their place in the management of RBD.
Melatonin is indicated for the treatment of chronobiological
disorders and insomnia, though is often prescribed off-label for
all other sleep disorders. One of melatonin’s main functions is to
synchronize circadian rhythms by binding to its receptors at the
hypothalamic suprachiasmatic nucleus (SCN) (96). Melatonin
has been shown to improve sleep quality and duration in both
healthy and diseased individuals (97, 98), and as sleep disorders
are often multi-factorial, prescribing melatonin or melatonin-
related compounds is often done to try to non-specifically
stabilize any underlying circadian desynchronizations. In the
case of RBD, where changes in REM circadian rhythmicity
have been shown (57, 99), blanket-prescription of melatonin
may be beneficial for patients. However, as no blinded case-
controlled trials have confirmed the stabilization of REM
circadian rhythmicity by melatonin in RBD, the clinical- and
cost-effectiveness of blanket prescription policy for healthcare
systems should be taken into consideration by the clinician (100).
Enhancement of melatonin signaling within the brain can
be achieved directly with an exogenous, modified release
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form of melatonin or indirectly with the melatonin receptor
agonist Ramelteon. Melatonin is usually prescribed to treat
RBD behavioral symptoms in the context of clonazepam
shortcomings—either as a replacement monotherapy (if the
patient cannot tolerate clonazepam due to side effects) or as
a polytherapy in combination with clonazepam (if clonazepam
is insufficient in controlling RBD symptoms and residual sleep
behaviors persist).
The evidence for melatonin’s efficacy is variable: several
studies have found it to reduce RBD motor behavior occurrence
(101–103), with long-term use ameliorating RBD symptoms
in the majority of patients (104). However, a recent placebo-
controlled trial found melatonin use at either 2 or 6 mg/night
improved self-reported measures such as daytime sleepiness,
sleep quality or dream enactment behaviors (105). A recent
randomized, controlled trial of melatonin in a cohort of PD
patients with RBD also found no effect of melatonin on RBD
symptom frequency or severity (106), suggesting melatonin may
be less effective at controlling RBD symptoms in the context
of advanced neurodegeneration. The efficacy of melatonergic
compounds such as the melatonin receptor agonist Ramelteon
also do not significantly improve RBD symptom severity (107).
As melatonin causes fewer side effects has low tolerance risk
and few drug interactions, it may be more suitable for RBD
patients than clonazepam (108). Despite this, the uncertainty
around melatonin’s mechanism of action and overall efficacy
means the popularity of clonazepam prevails.
At the time of writing, the UK RAG drug classification lists
melatonin as a RED drug and clonazepam as a GREEN drug.
The prescription of melatonin therefore requires secondary or
tertiary care initiation and management whereas clonazepam
prescription can be managed by GPs. This may be a choice-
limiting factor for some patients. Ultimately, it is a combination
of the clinician’s personal preference and best judgement of which
drug is prescribed.
SYMPTOM MONITORING
Follow-up studies and projected conversion rates estimate
that the majority of idiopathic RBD patients will develop a
clinically-defined α-synucleinopathy within 8 years of their initial
diagnosis (18). Despite this, there are no guidelines for the
routine monitoring of RBD patient symptomology (95). What
further limits any attempts at symptom tracking is the lack of
standardized clinical rating scales for RBD severity progression
and conversion. The discrepancy between a lack of clinician-
instigated patient follow up vs. the high risk of α-synucleinopathy
development is largely explained by the fact that there are no
medical interventions to stop or slow RBD conversion. The
benefits of tracking neurodegenerative symptoms are therefore
greatly outweighed by the economic cost to the healthcare system
and the emotional burden to the patient.
The immediacy of such a situation, wherein both clinician
and patient are powerless, can make symptom monitoring
unattractive. Therefore, to date, the majority such follow up tends
to be confined to research studies. Below, we detail how current
practice in RBDmanagement could be feasibly improved without
changes to existing healthcare practices or clinic frameworks and
explore possibilities for the development of a prodromal rating
scale to track idiopathic RBD symptomology.
Ideally, once RBD has been confirmed on v-PSG, the newly
diagnosed patient should undergo a series of standardized
functional assessments to determine their current or “baseline”
symptoms. These assessments should address the range of deficits
which have been associated with RBD (and subsequent α-
synucleinopathy development) in the literature and should be
sensitive enough to capture subtle dysfunctions. Ultimately, the
development of a unified assessment scale for clinical-practice
deployment to RBD patients is recommended. This should be
reflective of theMovement Disorders Society’s recently published
research criteria for prodromal PD (109), which demonstrates
relatively high sensitivity for prediction of PD development
(110). RBD patients should then be seen annually to discuss
their disease phenotype with their clinician, and to repeat the
functional assessments. This would generate an in-depth profile
of each patient and their symptoms and ensure early signs of
neurodegeneration can be addressed using available clinical tools.
CURRENT RESEARCH: RBD AND THE
α-SYNUCLEINOPATHIES
The tests described in this section are used solely in experimental
settings and therefore clinicians are not able to use them in
the clinical RBD diagnostic or prognostic process. The majority
of RBD research focuses upon the relationship between RBD
and subsequent α-synucleinopathy development. In particular,
the search for biomarkers which identify underlying α-synuclein
pathology and predict RBD phenoconversion is perhaps the
most relevant for clinical practice. As discussed previously
there are no genetic markers with predictive power for
RBD phenoconversion, and while rating scales may identify
individuals with a high risk of phenoconversion, they do not
have a binary outcome measure- a feature which is essential in
prognostic testing.
Biomarkers for RBD conversion are essentially testing whether
the RBD features of an individual are due to underlying
α-synuclein pathology or not. This can be done by testing
for misfolded, pathological α-synuclein (typically identified by
serine-129 phosphorylation) in peripheral tissues and fluid
samples. Dermal nerve fibers (111, 112), cerebrospinal fluid
(113), submandibular glands (114), colonic submucosal nerve
fibers (115), salivary glands (116), and parotid glands (117)
have all been found to contain pathological α-synuclein proteins
in idiopathic RBD patient populations and confirmatory PD
populations. Such investigations are in their infancy but show
promise as a basis for relatively low-cost clinical diagnostic biopsy
tests for alpha-synucleinopathy in RBD patients.
Bioimaging techniques, such as MRI and PET scanning,
are a less invasive alternative to biopsy-based diagnostic tests.
Such methods are capable of identifying and quantifying
dysfunction in deep structures which may otherwise be
inaccessible. In general, the greatest focus has been upon
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tissues and neurotransmitters whose dysfunction corresponds
to the symptoms of α-synucleinopathies as there are no tracer
molecules for direct pathological α-synuclein visualization. The
degeneration of dopaminergic neurons seen in PD, and to some
extent DLB, has led to an emphasis on imaging dopamine-
associated molecules, such as dopamine and non-specific
monoamine transporters, in RBD patients (118). DaTSCANs,
which are a way to visualize presynaptic dopamine transporter
density, are already used clinically in the diagnosis of PD and
may also be enlisted in confirming whether an RBD individual
has degeneration of dopaminergic terminals projecting to the
putamen. However, RBD onset likely precedes gross dopamine
dysfunction, and this is reflected in the literature that not all
RBD patients present with abnormal DaTSCAN (18). Efforts to
image neurotransmitter systems which may be affected earlier
in the prodromal period accompanying RBD symptoms are
therefore underway. Perhaps the most thorough and ambitious
of these efforts demonstrated multimodal characterization of the
sympathetic, parasympathetic, noradrenergic, and dopaminergic
systems in RBD patients, using a combination of MRI, PET,
CT, and scintigraphy (15). The authors found that the RBD
patients had abnormal peripheral autonomic nervous system and
brainstem results, but few demonstrated cerebral pathology (15).
These results are in line with both clinical DaTSCAN findings
and the Braak staging model of pathology and argue against the
use of DaTSCAN for RBD diagnosis or prognosis prediction.
Though providing a useful insight into the progression and
extent of neurodegeneration in an individual, there are several
caveats to the use of imaging tests in regular diagnostic or
prognostic practice. As seen above, DaTSCANs are unlikely
to yield valuable results in an RBD patient, making the tests
highly uneconomical. Multiple imaging tests are also inherently
accompanied by radiation exposure and its associated risks.
Therefore, while there is potential for assessment of alternative
neurotransmitter systems in RBD patients, the clinical value of
such tests must be assessed further. As with the majority of tests,
neuroimaging currently adds to the overall picture rather than
produces a binary diagnostic or prognostic outcome.
α-SYNUCLEINOPATHY TREATMENTS
Advances in preventative, slowing or curative α-
synucleinopathy treatments would add credence to RBD
patient monitoring, as the potential for therapeutic deployment
during the RBD-characterized prodromal period could
significantly disrupt the disease trajectory. Development
of antibodies against pathological α-synuclein (119, 120)
and neurorestorative/neuroprotective compounds (121) hold
promise for treatments but as yet there are no clinically-approved
α-synucleinopathy therapies.
CONCLUSIONS
RBD presents a multitude of considerations relevant for
neurologists and non-specialized clinicians alike. From a public
health perspective, RBD highlights the importance of sleep for
good health and the need for greater awareness of sleep disorders
and their detrimental effects. For scientists and researchers, RBD
represents a window of opportunity for deployment of new
interventions against neurodegenerative processes, as well as an
opportunity to gain insight into the complex neural mechanisms
of sleep and wake. Finally, the diagnosis, treatment, and ethical
considerations of RBD require the clinician to demonstrate
cross-speciality knowledge, emphasizing the importance and
challenges of sleep medicine training in an over-stretched
education system which provides inadequate training on sleep
and it’s disorders (122–124).
The dream enactment characteristic of RBD is associated
with a variety of root causes- from acute emotional states
to progressive neurodegeneration. The biological mechanisms
underpinning the intrusion of waking behaviors into REM sleep
remain to be fully characterized, plus it remains to be seen
whether the samemechanisms underlie different disorders which
share the symptom of dream enactment. For the majority of RBD
patients, dream enactment behaviors will be the first symptom
of impending α-synucleinopathic disease. Thus, the onus lies
with the clinician to recognize these risks, communicate them
effectively, and diagnose accordingly. While the prognosis of
idiopathic RBD remains uncertain, an increase in basic and
clinical research into the condition is already leading to greater
understanding and endpoint prediction. The final barrier to RBD
patient care remains effective treatments to slow, reverse, or stop
the effects of α-synuclein mediated disease.
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